Understanding how specific histone variants help cells respond to DNA damage
Shaping DNA Damage Response Networks Via Histone H2A Variants
This study is looking at how certain proteins called histone H2A variants help cancer cells fix their DNA when it's damaged, which could lead to better treatments for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11056120 on NIH RePORTER |
What this research studies
This research investigates the role of histone H2A variants in the cellular response to DNA damage, particularly in cancer cells. By using advanced biochemical techniques and cell models, the study aims to uncover how these histone variants interact with other proteins to facilitate DNA repair processes. The research focuses on understanding the mechanisms by which these variants influence cellular responses to radiation and specific cancer treatments, potentially leading to improved therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that involve DNA damage and repair mechanisms.
Not a fit: Patients with non-cancerous conditions or those whose DNA damage responses are not related to histone variants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new approaches in cancer treatment by enhancing the effectiveness of therapies that target DNA repair mechanisms.
How similar studies have performed: Previous research has shown promising results in understanding the role of histone variants in DNA repair, indicating that this approach has potential for significant advancements in cancer treatment.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Miller, Kyle M — Emory University
- Study coordinator: Miller, Kyle M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.